Bayer Pharmaceuticals is set to roll out two new therapies in 2025 as part of its focus on strengthening its cardiology and women’s health portfolios. The company is gearing up for a landmark launch year amid strategic R&D investments and efforts to overcome a high debt load.
New Launches in Cardiology and Women’s Health
In the cardiology segment, Bayer will introduce a treatment for transthyretin amyloid cardiomyopathy in Europe and a new therapy for heart failure patients with preserved ejection fraction (HFpEF)—a condition affecting a large patient base with limited treatment options.
In women’s health, Bayer plans to launch an innovative hormone-free therapy for menopausal vasomotor symptoms (hot flashes), showing promising results in Phase III trials. Regulatory submissions are underway in both the U.S. and Europe.
Driving R&D with a Focused Growth Strategy
Backed by major investments in R&D, Bayer is advancing a differentiated pipeline across oncology, cardiovascular, neurology, and immunology. The company also continues to make strides in cell and gene therapy, with notable progress in Parkinson’s disease treatment—including investigational cell and gene therapies through subsidiaries BlueRock Therapeutics and AskBio.
Bayer’s cardiovascular pipeline also includes gene therapy for congestive heart failure, currently in Phase II trials, and reflects its shift toward precision cardiology.
Oncology Pipeline and Precision Medicine
In oncology, Bayer is strengthening its position in prostate cancer treatment and expanding its targeted radionuclide therapy (TRT) platform. It currently has two actinium-225 based therapies in Phase I trials for metastatic prostate cancer, alongside precision molecular oncology programs for solid and blood cancers.
The company also announced progress in developing next-gen immuno-oncology drugs and small-molecule therapies through recent acquisitions like Tavros Therapeutics, enhancing its chemoproteomics capabilities.
Vision for the Future
Bayer’s leadership underscores that 2025 will be a turning point, as the company brings blockbuster potential drugs to market. The pipeline reflects Bayer’s push toward treating complex diseases, expanding patient access, and accelerating global innovation across therapeutic areas.
With its broad late-stage pipeline, Bayer is positioning itself not only for commercial growth but also to address high unmet medical needs through transformative treatments in cardiology, oncology, neurology, and women’s health.